Delivering clarity for a better tomorrow.
PROSTATENOW™ is a comprehensive germline test for people with prostate cancer. This test can be used to predict prognosis among men with localized prostate cancer, predict therapeutic responses for advanced patients, and predict cancer risk among unaffected men.
Covered by Medicare for qualifying patients
Recommended by new NCCN guidelines
Supported by top peer reviewed publications
Why should urologists consider PROSTATENOW™ ?
Who benefits from PROSTATENOW™ ?
How do urologists incorporate PROSTATENOW™ into their practice?
PROSTATENOW™ is the only test today that assesses a patient’s risk based on all three methods:
Family History (FH)
FH is a common but indirect measurement of inherited risk.
Men with a positive FH have a 1.5-to-2.5-fold increased risk for developing prostate cancer.
Rare Pathogenic Mutations (RPMs)
RPMs are pathogenic DNA mutations in the coding regions of genes such as BRCA2, ATM, and CHEK2.
RPMs are associated with a moderate-to-high risk for developing prostate cancer. Also associated with prostate cancer aggressiveness.
Genetic Risk Score (GRS)
Calculated based on more than 100 single nucleotide polymorphisms (SNPs) associated with prostate cancer risk.
Used to assess a man’s risk of developing prostate cancer compared to other men in the general population.
Benefits of PROSTATENOW™
Assess prognosis for localized prostate cancer patients
Recommends therapeutic responses for advanced prostate cancer patients
Assess risk for unaffected men
How PROSTATENOW™ testing works
Physician & patient discuss the benefits of PROSTATENOW™.
The test can be performed using blood or saliva
Your Sample is Analyzed in our Lab
Your PROSTATENOW™ report will be available within 10-14 days.
We're here to guide you through the process.
Part of PROSTATENOW™ includes genetic counseling to walk you through our process and test results, along with any lifestyle or treatment alternatives depending on your results.